Sabera Shah, MD
- Adult Diabetes, Eye Care
Opthalmologist
Assistant Professor of Ophthalmology, Harvard Medical School
Dr. Shah has devoted her professional career as a staff ophthalmologist at the Beetham Eye Institute of the Joslin Diabetes Center. Her major clinical practice focus is on diabetic eye disease, which involves managing complex diabetic eye disease and performing complex cataract evaluation and surgical care averaging approximately 150 laser procedures per year and 4,000 patient visits per year.
Beginning in 2017, she shifted her focus to caring predominantly for cataract surgery in the presence of diabetic eye disease, and she performs approximately 45 cataract surgeries per month. She has participated in Research efforts involve participation in numerous clinical trials as a co-investigator, including the Early Treatment Diabetic Retinopathy Study, the Diabetes Control and Complications Trial, the Epidemiology of Diabetes Interventions and Complications Study, and clinical trials of the Diabetic Retinopathy Clinical Research Network conducted at the Beetham Eye Institute.
- Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
- Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema
- Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time
- Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time
- Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
- Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema